Renan Jin

1.8k citations
34 papers · 1.2k indexed · 1 hit paper · h-index 17

Renan Jin

30 papers receiving 1.2k citations

Hit Papers

CircRNA-SORE mediates sorafenib resistance in hepatocellu...3322020202620222024100200300

Peers

Renan Jin
Comparison fields: 5 of 76
  • Hepatology 258
  • Cancer Research 463
  • Molecular Biology 703
  • Oncology 274
  • Pathology and Forensic Medicine 133
Replace Jiliang Shen with:
Jiliang Shen China
Zhenggang Ren China
So Mee Kwon South Korea
Hien Dang United States
Kejun Nan China
Daimin Xiang China
Tong‐Chun Xue China
Jianting Long China
Arihiro Aihara Japan
Renan Jin relative to Jiliang Shen China Jiliang Shen's profile →
Citations per field
00.5×3.8×
Jiliang Shen · 1×
Citations per year

Countries citing papers authored by Renan Jin

Since Specialization
Citations

This map shows the geographic impact of Renan Jin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Renan Jin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Renan Jin more than expected).

Fields of papers citing papers by Renan Jin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Renan Jin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Renan Jin. The network helps show where Renan Jin may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Renan Jin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Renan Jin Line = papers co-authored together Renan Jin links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20250
3 20241
4 20231
5 20230
6 20225
7 202211
8
CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1breakdown →
2020332
9 201818
10 201715
11 201757
12 201617
13 201625
14 20157
15 201527
16 2015208
17 201479
18 201428
19 20136
20 201117

About Renan Jin

Renan Jin is a scholar working on Hepatology, Cancer Research and Pathology and Forensic Medicine, having authored 34 papers that have together received 1.2k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (9 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers), Pediatric Hepatobiliary Diseases and Treatments (5 papers), Cancer Mechanisms and Therapy (5 papers), MicroRNA in disease regulation (4 papers), Pancreatic and Hepatic Oncology Research (3 papers), Liver Disease Diagnosis and Treatment (3 papers) and Gallbladder and Bile Duct Disorders (3 papers). The work is most often cited by research in Hepatology (258 citations), Cancer Research (463 citations) and Molecular Biology (703 citations). Renan Jin has collaborated with scholars based in China, United States and Taiwan. Frequent co-authors include Xiujun Cai, Yuelong Liang, Xiao Liang, Hui Lin, Hong Yu, Junjie Xu, Jinghua Liu, Xiaomin Song, Lin Ji and Jie Zhao. Their work appears in journals such as Surgical Endoscopy, Cell Death and Disease, Oncotarget, Journal of Gastrointestinal Surgery and Cell & Bioscience.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026